BFM
SABS icon

Boothbay Fund Management’s SAB Biotherapeutics SABS Stock Holding History

Boothbay Fund Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.67M Buy
+1,481,660
New +$5.91M 0.07% 285
2021
Q3 		– Sell
-40,000
Closed -$3.98M – 2148
2021
Q2 		$3.98M Buy
+40,000
New +$3.97M 0.13% 176

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Boothbay Fund Management's SABS Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in SAB Biotherapeutics (SABS) in Q1 2026: 1,481,660 shares worth $5.67M. The stake represents 0.07% of the portfolio and ranks #285 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in SABS as recently as Q2 2021.

Boothbay Fund Management first reported a position in SABS in Q2 2021 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Boothbay Fund Management held 1,481,660 shares of SAB Biotherapeutics worth $5.67M as of Q1 2026.
  • SAB Biotherapeutics was a new Boothbay Fund Management position in Q1 2026.
  • SAB Biotherapeutics made up 0.07% of Boothbay Fund Management's portfolio in Q1 2026, its #285 holding.
  • Boothbay Fund Management first reported a position in SAB Biotherapeutics in Q2 2021 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.